Project 2: Metabolic and Immune Systems of Biology Interactions as Initiators and Drivers of Alzheimer's Pathology in Brain: Therapeutic Targets and Windows
项目 2:生物相互作用的代谢和免疫系统作为大脑中阿尔茨海默病病理学的引发剂和驱动因素:治疗目标和窗口
基本信息
- 批准号:10412249
- 负责人:
- 金额:$ 57.11万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2006
- 资助国家:美国
- 起止时间:2006-08-15 至 2026-05-31
- 项目状态:未结题
- 来源:
- 关键词:AddressAgingAlzheimer&aposs DiseaseAlzheimer&aposs disease pathologyAlzheimer&aposs disease riskAmericanAnti-Inflammatory AgentsApolipoprotein EAutoimmune DiseasesBioenergeticsBioinformaticsBiologicalBiologyBrainCellsChronologyComplexEndocrineFemaleFoundationsGeneticGenotypeGoalsImmuneImmune responseImmune systemImmunotherapeutic agentLeadMapsMedicalMedicineMenopauseMetabolicMissionMusNational Institute on AgingNeuroimmuneNeuroimmune systemNeurosecretory SystemsOutcomePathway interactionsPerimenopausePharmaceutical PreparationsPhenotypePopulationPostmenopausePrecision therapeuticsResearchSystems BiologyTherapeuticTimeTranslatingWomanaging brainapolipoprotein E-4basedisease phenotypeendophenotypegene networkimmunomodulatory therapiesimmunoregulationinsightmeetingsmetabolomicsmiddle agepre-clinicalpreventprogramsrelating to nervous systemresponsetargeted treatmenttherapeutic candidatetherapeutic targettranscriptometranscriptomicstranslational goal
项目摘要
PROJECT SUMMARY – PROJECT 2
The mission of the Perimenopause in Brain Aging and Alzheimer’s disease (P3) is to discover biological
transformations in brain that occur during the perimenopausal transition that lead to endophenotypes predictive
of risk for Alzheimer’s disease (AD). Each year ~1.5 million American women enter into the perimenopause, a
neuroendocrine transition state unique to the female. Herein, we focus on the neuro-immune system as a key
driver of chronological and endocrinological aging that occurs in the midlife female brain. Our goals are to identify
the mechanisms by which these transformations occur and to translate these discoveries into strategies to
prevent conversion to an at-Alzheimer's-risk phenotype. Project 2 contributes to achieving P3 goals by
determining the systems of immune biology activated across midlife chronological and endocrinological aging,
the dynamic conversions in immune transcriptome and phenotype, the contributing cells, the map of neural
immune responses and therapeutics that specifically target each stage of immune conversion. The overall
hypothesis guiding Project 2 program of research is that the immune system is the initiator and driver of the
metabolic crisis in brain. Based on our preliminary evidence, we anticipate that the neuro-immune profile in brain
will be dynamic and endocrine aging stage dependent. Further, we hypothesize that APOE genotype will be a
key regulator of the neuro-immune system of biology in brain. Aim 1 addresses fundamental systems biology of
the interface between the bioenergetic and immune systems in brain. Aim 1 analyses will determine the dynamic
neuro-immune genotypic/phenotypic signatures that emerge over the course of the pre, peri, and
postmenopausal transition. The goal of Aim 2 is to establish a foundation for precision immune modulating
therapies for reduction of Alzheimer’s disease risk in women based on endocrine aging status and APOE
genotype which will be achieved through computational medical bioinformatics strategies. The translational goal
of Aim 3 is to create a platform for precision neuro-immune therapy based on APOE4 genetic burden and
endocrine aging status. Aim 3 objectives will be achieved by: 1) integrating neuro-immune signatures derived
from Aim 1 with therapeutic candidates from Aim 2; 2) treating hAPOE mice with neuro-immune therapy specific
to endocrine aging transition; 3) determining efficacy of precision neuro-immune therapy to prevent, delay and
treat hallmark pathologies of Alzheimer’s disease. Collectively, outcomes of these analyses will provide a
platform on which to achieve precision neuro-immune medicine to intervene with the right therapy at the right
time in the right APOE genotype.
Research proposed herein addresses strategic goals of the National Institutes on Aging’s 2016: Aging Well in
the 21st Century: Strategic Directions for Research on Aging, specifically Goals A1, 2, 3, 7, 8 & 11 and Goals
D1, 2, & 4.
项目概要-项目2
在脑老化和阿尔茨海默病(P3)围绝经期的使命是发现生物学
在围绝经期过渡期间发生的大脑中的转变,导致内表型预测
阿尔茨海默病(AD)的风险。每年约有150万美国妇女进入围绝经期,
女性特有的神经内分泌过渡状态。在这里,我们专注于神经免疫系统作为一个关键,
中年女性大脑中发生的时间和内分泌老化的驱动因素。我们的目标是找出
这些转变发生的机制,并将这些发现转化为战略,
防止转化为阿尔茨海默氏症风险表型。项目2通过以下方式帮助实现项目3目标:
确定免疫生物学系统在中年时间和内分泌衰老中激活,
免疫转录组和表型的动态转换,贡献细胞,神经细胞图,
免疫应答和特异性靶向免疫转化每个阶段的治疗剂。整体
指导项目2研究计划的假设是,免疫系统是免疫系统的启动者和驱动者。
大脑代谢危机。基于我们的初步证据,我们预期大脑中的神经免疫状况
将取决于动态和内分泌衰老阶段。此外,我们假设APOE基因型将是一个
大脑中生物学神经免疫系统的关键调节器。目标1涉及基础系统生物学,
大脑中生物能量和免疫系统之间的接口。目标1分析将确定动态
神经免疫基因型/表型签名,出现在过程中的前,后,
绝经后过渡期目标二是为精确的免疫调节奠定基础
基于内分泌衰老状态和载脂蛋白E降低女性阿尔茨海默病风险的疗法
基因型,这将通过计算医学生物信息学策略实现。翻译目标
目标3是建立一个基于APOE 4遗传负荷的精确神经免疫治疗平台,
内分泌衰老状态目标3的目标将通过以下方式实现:1)整合来自神经免疫签名,
2)用来自目标2的治疗候选物治疗hAPOE小鼠;
向内分泌衰老过渡; 3)确定精确神经免疫治疗的功效,以预防、延迟和
治疗阿尔茨海默病的标志性病理。总的来说,这些分析的结果将提供
平台上,实现精准神经免疫医学干预与正确的治疗在正确的
时间在正确的APOE基因型。
本文提出的研究解决了国家老龄化研究所2016年的战略目标:
世纪:老龄化研究的战略方向,特别是目标A1、2、3、7、8和11以及目标
D1、2和4。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
ROBERTA EILEEN BRINTON其他文献
ROBERTA EILEEN BRINTON的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('ROBERTA EILEEN BRINTON', 18)}}的其他基金
Translational Research in Alzheimer's Disease and related Dementias (TRADD)
阿尔茨海默病和相关痴呆症的转化研究 (TRADD)
- 批准号:
10709167 - 财政年份:2023
- 资助金额:
$ 57.11万 - 项目类别:
Novel Intranasal Formulations of Allopregnanolone, a Regenerative Therapeutic for Alzheimer's Disease
Allopregnanolone 的新型鼻内制剂,一种阿尔茨海默病的再生疗法
- 批准号:
10698555 - 财政年份:2023
- 资助金额:
$ 57.11万 - 项目类别:
PhytoSERM Efficacy to Prevent Menopause Associated Decline in Brain Metabolism and Cognition: A Double-Blind, Randomized, Placebo-Controlled Phase 2 Clinical Trial
PhytoSERM 预防更年期相关脑代谢和认知能力下降的功效:双盲、随机、安慰剂对照 2 期临床试验
- 批准号:
10560591 - 财政年份:2022
- 资助金额:
$ 57.11万 - 项目类别:
PhytoSERM Efficacy to Prevent Menopause Associated Decline in Brain Metabolism and Cognition: A Double-Blind, Randomized, Placebo-Controlled Phase 2 Clinical Trial
PhytoSERM 预防更年期相关脑代谢和认知能力下降的功效:双盲、随机、安慰剂对照 2 期临床试验
- 批准号:
10344556 - 财政年份:2022
- 资助金额:
$ 57.11万 - 项目类别:
PhytoSERM for Menopausal Hot Flashes and Sustained Brain Health
PhytoSERM 针对更年期潮热和持续大脑健康
- 批准号:
10547639 - 财政年份:2022
- 资助金额:
$ 57.11万 - 项目类别:
PhytoSERM for Menopausal Hot Flashes and Sustained Brain Health
PhytoSERM 针对更年期潮热和持续大脑健康
- 批准号:
10707107 - 财政年份:2022
- 资助金额:
$ 57.11万 - 项目类别:
Regulatory and Human Study Operations (RHSO) Core C
监管和人体研究运营 (RHSO) 核心 C
- 批准号:
10689308 - 财政年份:2021
- 资助金额:
$ 57.11万 - 项目类别:
Regulatory and Human Study Operations (RHSO) Core C
监管和人体研究运营 (RHSO) 核心 C
- 批准号:
10491851 - 财政年份:2021
- 资助金额:
$ 57.11万 - 项目类别:
Regulatory and Human Study Operations (RHSO) Core C
监管和人体研究运营 (RHSO) 核心 C
- 批准号:
10270190 - 财政年份:2021
- 资助金额:
$ 57.11万 - 项目类别:
相似海外基金
Interplay between Aging and Tubulin Posttranslational Modifications
衰老与微管蛋白翻译后修饰之间的相互作用
- 批准号:
24K18114 - 财政年份:2024
- 资助金额:
$ 57.11万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
The Canadian Brain Health and Cognitive Impairment in Aging Knowledge Mobilization Hub: Sharing Stories of Research
加拿大大脑健康和老龄化认知障碍知识动员中心:分享研究故事
- 批准号:
498288 - 财政年份:2024
- 资助金额:
$ 57.11万 - 项目类别:
Operating Grants
EMNANDI: Advanced Characterisation and Aging of Compostable Bioplastics for Automotive Applications
EMNANDI:汽车应用可堆肥生物塑料的高级表征和老化
- 批准号:
10089306 - 财政年份:2024
- 资助金额:
$ 57.11万 - 项目类别:
Collaborative R&D
Baycrest Academy for Research and Education Summer Program in Aging (SPA): Strengthening research competencies, cultivating empathy, building interprofessional networks and skills, and fostering innovation among the next generation of healthcare workers t
Baycrest Academy for Research and Education Summer Program in Aging (SPA):加强研究能力,培养同理心,建立跨专业网络和技能,并促进下一代医疗保健工作者的创新
- 批准号:
498310 - 财政年份:2024
- 资助金额:
$ 57.11万 - 项目类别:
Operating Grants
関節リウマチ患者のSuccessful Agingに向けたフレイル予防対策の構築
类风湿性关节炎患者成功老龄化的衰弱预防措施的建立
- 批准号:
23K20339 - 财政年份:2024
- 资助金额:
$ 57.11万 - 项目类别:
Grant-in-Aid for Scientific Research (B)
Life course pathways in healthy aging and wellbeing
健康老龄化和福祉的生命历程路径
- 批准号:
2740736 - 财政年份:2024
- 资助金额:
$ 57.11万 - 项目类别:
Studentship
I-Corps: Aging in Place with Artificial Intelligence-Powered Augmented Reality
I-Corps:利用人工智能驱动的增强现实实现原地老龄化
- 批准号:
2406592 - 财政年份:2024
- 资助金额:
$ 57.11万 - 项目类别:
Standard Grant
NSF PRFB FY 2023: Connecting physiological and cellular aging to individual quality in a long-lived free-living mammal.
NSF PRFB 2023 财年:将生理和细胞衰老与长寿自由生活哺乳动物的个体质量联系起来。
- 批准号:
2305890 - 财政年份:2024
- 资助金额:
$ 57.11万 - 项目类别:
Fellowship Award
虚弱高齢者のSuccessful Agingを支える地域課題分析指標と手法の確立
建立区域问题分析指标和方法,支持体弱老年人成功老龄化
- 批准号:
23K20355 - 财政年份:2024
- 资助金额:
$ 57.11万 - 项目类别:
Grant-in-Aid for Scientific Research (B)
「ケア期間」に着目したbiological aging指標の開発
开发聚焦“护理期”的生物衰老指数
- 批准号:
23K24782 - 财政年份:2024
- 资助金额:
$ 57.11万 - 项目类别:
Grant-in-Aid for Scientific Research (B)